Mjp. Raatikainen et al., ELECTROPHYSIOLOGICAL EFFECTS OF A NOVEL, SHORT-ACTING AND POTENT ESTER DERIVATIVE OF AMIODARONE, ATI-2001, IN GUINEA-PIG ISOLATED HEART, The Journal of pharmacology and experimental therapeutics, 277(3), 1996, pp. 1454-1463
In this study the acute effects of ATI-2001, a recently developed este
r derivative of amiodarone, on heart rate, atrioventricular conduction
and frequency-dependent prolongation of ventricular conduction, repol
arization and refractoriness were investigated in guinea pig isolated
heart. Compared with amiodarone, an equimolar concentration of ATI-200
1 (1 mu M) caused significantly greater slowing of heart rate, depress
ion of atrioventricular and intraventricular conduction and prolongati
on of ventricular repolarization. Unlike amiodarone, the effects of AT
I-2001 were significantly reversed during washout of the drug. ATI-200
1 exhibited frequency-independent effects on ventricular repolarizatio
n and refractoriness. It prolonged base-line ventricular monophasic ac
tion potential duration by 10%, 8%, 9% and 9% and ventricular effectiv
e refractory period by 24%, 20%, 22% and 26% at cycle lengths of 350,
300, 250 and 200 msec, respectively. Thus, ATI-2001 (1 mu M) increased
the ventricular effective refractory period/action potential duration
ratio, suggesting both time- and voltage-dependent prolongation of ve
ntricular refractoriness. In addition, ATI-2001 lengthened ventricular
conduction times (QRS interval and basic conduction time) significant
ly more at shorter cycle lengths. Conversely, d-sotalol, a pure class
III antiarrhythmic agent, had no effect on ventricular conduction time
s and exhibited a reverse frequency-dependent effect on ventricular re
polarization. In summary, the electrophysiological effects of ATI-2001
were greater and more rapidly reversible than those of amiodarone. Th
e lack of reverse frequency-dependent effects on ventricular repolariz
ation and refractoriness suggests that ATI-2001 may be more efficaciou
s than d-sotalol or other pure class III drugs in treating ventricular
tachycardias and less likely to become proarrhythmic at normal or slo
w heart rates.